Compare Enveric Biosciences Inc (ENVB) vs Hasbro, Inc. (HAS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Hasbro, Inc. — how do they compare? Enveric Biosciences Inc trades at $1.37 (market cap $5.32M), while Hasbro, Inc. trades at $80.4 (market cap $11.39B). The key difference: Hasbro, Inc. is far larger — about 2141× Enveric Biosciences Inc's market cap, and Hasbro, Inc. pays a 3.48% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | HAS | |
|---|---|---|
Market Cap | $5.32M | $11.39B |
Sector | Health | Consumer Cyclical |
52-Week High | $17.40 | $105.88 |
52-Week Low | $1.28 | $70.95 |
Enterprise Value | $408.82K | $13.66B |
Dividend Yield | — | 3.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.38, up 4.55% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of $8.77M for 2025, though it beat EPS estimates in all four quarters. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003, including IND-enabling studies and positive preclinical results.
Outlook hinges on clinical progress, with 75% analyst buy ratings supporting potential upside, but high financial losses and negative ROE/ROA pose significant risks. Investors face volatility from regulatory developments and funding needs, making it speculative despite positive sentiment from recent operational updates.
Hasbro (HAS) trades at $81.65, up 4.12% today, but remains in a bearish technical trend. The company reported negative net income of -$322.40M for 2025 despite revenue growth to $4.70B, with profitability metrics like ROE at -24.49% reflecting challenges. Recent news highlights product innovation like Blooms by Play-Doh targeting adults, while earnings have consistently beaten expectations in recent quarters, suggesting potential operational resilience amid financial headwinds.
The outlook is mixed: analyst consensus is bullish with a $105.43 price target (51.52% buy ratings), but high debt and negative margins pose risks. Upside hinges on earnings turnaround and successful adult-focused product launches, while competitive pressures and macroeconomic factors could hinder recovery. Investors should weigh strong analyst sentiment against fundamental weaknesses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Hasbro, Inc.
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. Ownership stakes in Discovery Family, which offers programming around Hasbro brands, and owned production capabilities from Entertainment One help bolster Hasbro's multichannel presence. The firm acquired Entertainment One in 2019, bolting on popular properties like Peppa Pig and PJ Masks, and has plans to tie up with Dungeons & Dragons Beyond in 2022, offering the firm access 10 million digital tabletop players.
Read more on HAS →
